A qualitative review of issues arising in the use of psychostimulant medications in patients with ADHD and co‑morbid substance use disorders
- 8 April 2008
- journal article
- review article
- Published by Taylor & Francis Ltd in Current Medical Research and Opinion
- Vol. 24 (5), 1345-1357
- https://doi.org/10.1185/030079908x280707
Abstract
Objective: This review addresses the relationship between attention-deficit/hyperactivity disorder (ADHD) and substance use disorders (SUDs), with an emphasis on factors that determine the potential for psychostimulant abuse. Strategies for identification and treatment of patients with ADHD who are at risk for, or have, co-morbid SUD are also addressed. Research design and methods: The article was based on a qualitative review of current literature addressing co-morbid ADHD and SUD. Discussion: Adolescent and adult patients with ADHD are at increased risk for SUD, as well as a number of other psychiatric disorders. Psychostimulant agents like methylphenidate (MPH) and mixed amphetamine salts (MAS) are effective first-line pharmacotherapies for ADHD; however, they are Schedule II controlled substances with a potential for abuse. Evidence suggests that treatment of ADHD during childhood with stimulant agents may reduce the risk of developing SUD later on. Factors associated with the highest risk of SUD in patients with ADHD include co-morbid antisocial personality disorder, bipolar disorder, an eating disorder, severe ADHD and/or antisocial behavior symptoms, and dropping out of school. Treatment initiation during adolescence or young adulthood also has been linked to increased risk of polydrug use and non-medical stimulant use, a pattern of behavior consistent with a risk of SUD development. Treatment plans for patients with ADHD and co-morbid SUD should include behavioral interventions, careful monitoring, and when appropriate, pharmacotherapy. When oral formulations of psychostimulants are used at recommended doses and frequencies, they are unlikely to yield effects consistent with abuse potential in patients with ADHD. Long-acting stimulant formulations and non-stimulants, like atomoxetine or bupropion, have a lower potential for abuse, and provide several safe and effective treatment options for the development of a comprehensive management plan for patients with co-morbid ADHD and SUD. Conclusions: The present review is neither exhaustive nor systematic. Moreover, the reviewed studies vary widely with regards to methodology and patient populations. In light of these limitations, several conclusions are still warranted. Patients with ADHD are at increased risk for SUD. Under certain conditions, psychostimulants may be a pharmacologic option in the treatment of patients with co-morbid ADHD and SUD. However, clinicians should be mindful of the risks and benefits of this treatment approach in a high-risk population and should also bear in mind the labeling guidelines when working with this co-morbidity.Keywords
This publication has 65 references indexed in Scilit:
- A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adultsPsychological Medicine, 2007
- Adderall Abuse in Texas, 1998–2004Journal of Toxicology and Environmental Health, Part A, 2007
- Treatment Strategies for Co‐Occurring ADHD and Substance Use DisordersThe American Journal on Addictions, 2007
- Illicit Use of Specific Prescription Stimulants Among College Students: Prevalence, Motives, and Routes of AdministrationPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2006
- Medical Use, Illicit Use and Diversion of Prescription Stimulant MedicationJournal of Psychoactive Drugs, 2006
- A Pilot Study of Methylphenidate Preference Assessment in Children Diagnosed with Attention-Deficit/Hyperactivity DisorderJournal of Child and Adolescent Psychopharmacology, 2005
- Psychostimulant Treatment and Risk for Substance Abuse Among Young Adults with a History of Attention-Deficit/Hyperactivity Disorder: APopulation-Based, Birth Cohort StudyJournal of Child and Adolescent Psychopharmacology, 2005
- Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issuesPsychiatric Clinics of North America, 2004
- Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled StudyAmerican Journal of Psychiatry, 2002
- Influence of Gender on Attention Deficit Hyperactivity Disorder in Children Referred to a Psychiatric ClinicAmerican Journal of Psychiatry, 2002